Momenta will invest in three novel drugs and end development of all but two late-stage biosimilars under a new business strategy. The company is reducing its workforce by 50%, or about 110 employees.
Momenta Pharmaceuticals Inc. is exiting the biosimilar drug development space to redirect resources to novel pipeline drugs for immune-mediated diseases under a new business strategy brought about, in part, because of the delayed launch of Glatopa 40 mg by partner Sandoz International GMBH.
The decision, announced Oct
AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.
At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.
Vyepti revenues rise by nearly 70% in the first quarter.
As CEO Anderson backs high prices for innovative drugs in Europe
The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.
Vyepti revenues rise by nearly 70% in the first quarter.
Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.
